Molecular mechanisms for understanding the association between TMPRSS2 and beta coronaviruses SARS-CoV-2, SARS-CoV and MERS-CoV infection: scoping review

María Juliana Chaves-Medina1 · Juan Camilo Gómez-Ospina1 · Herney Andrés García-Perdomo1,2

Received: 26 December 2020 / Revised: 7 December 2021 / Accepted: 14 December 2021 / Published online: 25 December 2021
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021

Abstract
The aim of this scoping review was to identify knowledge gaps and to describe the current state of the research on the association between TMPRSS2 and the essential beta coronaviruses (Beta-CoVs) infection and the molecular mechanisms for this association. We searched MEDLINE (OVID), EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL). We included 13 studies. Evidence shows an essential role of TMPRSS2 in Spike protein activation, entry, and spread into host cells. Co-expression of TMPRSS2 with cell surface receptors (ACE2 or DPP4) increased virus entry. This serine protease is involved in the formation of large syncytia between infected cells. TMPRSS2 cleaved the Spike protein of SARS-CoV, SARS-CoV-2, and MERS-CoV, and increased virus propagation. Accumulating evidence suggests that TMPRSS2 is an essential protease for virus replication. We highlighted its critical molecular role in membrane fusion and the impact in viral mRNA replication, then promoting/driving pathogenesis and resistance.

Keywords TMPRSS2 · Gene · Betacoronavirus · SARS-CoV-2 · SARS-CoV · MERS-CoV

Introduction
Emerging coronaviruses can constitute a severe threat to human health. The subfamily Coronavirinae within the family Coronaviridae comprises viruses that cause respiratory, neurological, and intestinal symptoms in mammals and birds (Wang et al. 2020a, b). The severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in 2002 in Southern China. The Middle East respiratory syndrome coronavirus (MERS-CoV), which emerged in Saudi Arabia, was the pathogen responsible for severe respiratory disease outbreaks in 2012 (Huang et al. 2020).

On 11 March 2020, WHO declared COVID-19 infection a pandemic, and the number of individuals infected and deaths quickly raised. Then, it is essential to monitor viral evolution, infectivity, transmissibility, and pathogenicity (Wang et al. 2020a, b; Huang et al. 2020; WHO 2020). The disease affected patients with underlying chronic illness, but documented infections in health care workers indicated human-to-human transmission. Now, it is very established that SARS-CoV-2 is capable of widespread human-to-human transmission (Wang et al. 2020a, b). Acute respiratory distress syndrome (ARDS) and shock associate with pulmonary inflammation and extensive lung damage in patients (Wang et al. 2020a, b; Huang et al. 2020). However, nowadays, we do not entirely understand the pathophysiology of SARS-CoV-2 infection and SARS-CoV and MERS-CoV (Zhu et al. 2020).

TMPRSS2 gene encodes a self-membrane protein of 492 amino acids, which anchors to the plasma membrane. It converts to its form through autocatalytic cleavage between Arg255 and Ile256 (Shulla et al. 2011). After cleavage, the mature proteases are mostly membrane-bound, yet a noticeable portion of them can liberate into the extracellular milieu. TMPRSS2 predominantly expresses in the prostate, lungs, colon, liver, kidneys, and pancreas. Also, it activates protease-activated receptor 2 (PAR-2), a G-protein-coupled receptor, that causes the upregulation of matrix metalloproteinase-2 (MMP-2) and MMP-9, which are critical proteases
in the metastasis of tumor cells. Some reports have shown how this TMPRSS2-mediated pathway allows the spread and pathogenesis of SARS-CoV, demonstrating that infection in the presence of this protease could induce higher concentrations of pro-inflammatory cytokines and cytopathic effects (Shulla et al. 2011; Wang et al. 2020a, b). Moreover, this enzyme may have an activating effect on the receptor to which some coronaviruses bind, such as human ACE2, which gives it a replication potential in human cells (Wang et al. 2020a, b; Huang et al. 2020).

This study aimed to identify knowledge gaps and to describe the current state of the research on the association between TMPRSS2 and the essential beta coronaviruses (Beta-CoVs) infection and the molecular mechanisms for this association. Also, to make specific recommendations for future research.

**Methods**

We performed this scoping review according to the recommendations of the Joanna Briggs Institute (Peters et al. 2017).

**Eligibility criteria**

**Participants**

We included theoretical information, in vitro or in vivo studies, studies in animals, or in silico studies assessing the molecular mechanism to determine the association between TMPRSS2 and the betacoronavirus SARS-CoV-2, SARS-CoV, and MERS-CoV infection.

**Concept**

We focused on the molecular mechanisms that explain the association between this serine protease and the infection of this virus.

**Context**

We did not limit for language or setting.

**Exclusion criteria**

Studies that did not include information about TMPRSS2 and Spike protein of coronaviruses.

**Information sources**

We included studies (human, animal, reviews, systematic reviews, and primary studies) to respond to the two objectives. We searched the literature following medical subject headings (MeSh), Emtree language, Decs, and text words related. We searched MEDLINE (OVID), EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception to nowadays. To ensure literature saturation, we scanned references from relevant articles identified through the search, conferences, thesis databases, Open Grey, Google scholar, and clinicaltrials.gov.

**Data collection**

Two researchers reviewed each reference by title and abstract. Then they scanned full-texts of relevant studies, applied pre-specified inclusion and exclusion criteria, and extracted the data. Disagreements were resolved by consensus. Two trained reviewers using a standardized form independently extracted the following information from each article: author, publication year, study design, geographic location (origin), authors' names, title, objectives, methods, virus species, cleavage site, outcomes, funding source, and other key findings.

**Synthesis of results**

We descriptively showed the results, trying to respond to the two objectives. Results were also classified under main conceptual categories to facilitate comprehension.

**Results**

**Study selection**

We found 84 studies with the search strategies and three with other sources. After exclusions, we finally included 13 studies (Matsuyama et al. 2010; Matsuyama et al. 2020; Glowacka et al. 2011; Shulla et al. 2011; Shirato et al. 2013; Heurich et al. 2014; Shen et al. 2017; Reinke et al. 2017; Kleine-weber et al. 2018; Iwata-Yoshikawa et al. 2019; Bilinska et al. 2020; Zang et al. 2020; Hoffmann et al. 2020) in the qualitative analysis (Fig. 1).

**Characteristics of included studies**

Five studies evaluated SARS-CoV (Glowacka et al. 2011; Shulla et al. 2011; Heurich et al. 2014; Reinke et al. 2017; Matsuyama et al. 2020), two evaluated MERS-CoV (Shirato et al. 2013; Kleine-weber et al. 2018), two studies evaluated both (Shen et al. 2017; Iwata-Yoshikawa et al. 2019), and three others evaluated SARS-CoV-2 (Hoffmann et al. 2020; Matsuyama et al. 2020). Multiple essays were reporting the expression of TMPRSS2 in different cell lines. The authors frequently used 293 T cells, Vero, Vero E6, Caco-2,
or Calu-3 cells. For infecting the cells, six studies used a lentiviral vector as plasmids. Also, they used plasmids encoding TMPRSS2, ACE2, or DPP4. For analysis of antigens expression, detection of proteins, quantification of messenger-RNA (mRNA), studies performed western blot and/or Real Time-Polymerase Chain Reaction (RT-qPCR). The authors also used other techniques such as immunohistochemistry, electron microscopy, and next-generation sequence (Table 1).

**Primary outcome: molecular mechanisms**

We described the molecular mechanisms for the association between TMPRSS2 and beta-CoV infection in the following paragraphs. We described some additional information regarding this topic in Table 2.

**Cleavage and activation of spike protein**

The SARS-CoV spike protein (SARS-S) incorporates into the viral envelope and mediates viral entry into target cells. For this, the surface unit (S1) of SARS-S binds to the cellular receptor angiotensin-converting enzyme 2 (ACE2) and the transmembrane unit (S2), then fuses the viral membrane with a host cell membrane (Reinke et al. 2017; Iwata-Yoshikawa et al. 2019).
| Study                  | Country    | Virus     | Reference | Cells | Molecular template | Cluster                        |
|-----------------------|------------|-----------|-----------|-------|--------------------|--------------------------------|
| Reinke et al. (2017)  | Germany    | SARS-CoV  | Plasmids pCAGGS | Human embryonal kidney 293 T cells and African green monkey derived COS-7 cells were grown in Dulbecco’s modified Eagle’s medium | Western blot | Trypsin, TMPRSS2, cathepsin B/L |
| Heurich et al. (2014) | Germany    | SARS-CoV  | Plasmids pCAGGS and pcDNA3.1 zeo, lentiviral vector pNL-Luc-E-R | 293 T and Cos-7 cells were maintained in Dulbecco’s modified Eagle medium (DMEM; Gibco, Invitrogen) | Western blot | TMPRSS2, HAT, ADAM17 |
| Glowacka et al. (2011)| Germany    | SARS-CoV  | Plasmids pCAGGS, pcDNA3.1 zeo, pNL4-3 E-R-Luc | Vero E6 and 293 T cells | Western blot, qRT-PCR, Immunochemistry | TMPRSS2, TMPRSS4, mouse matriptase-3 |
| Shulla et al. (2011)  | United States | SARS-CoV | Plasmids pCAGGS, MCS (TMPRSS2 and TMPRSS11d), pcDNA3.1 (SARS S and ACEC9), pNL4.3-Luc R-E-, pCDM8-NL63 S | Vero E6, Vero and Vero-TMPRSS2 cells, lung tissue samples from SARS-CoV-infected cynomolgus monkeys | Western blot, qRT-PCR | TMPRSS2 |
| Matsuyama et al. (2010)| Japan      | SARS-CoV  | SARS-CoV Frankfurt 1 strain, recombinant vaccinia virus containing the gene encoding SARS-CoV-S | Vero E6, Vero and Vero-TMPRSS2 cells, lung tissue samples from SARS-CoV-infected cynomolgus monkeys | Western blot, qRT-PCR | TMPRSS2 |
| Shirato et al. (2013) | Japan      | MERS-CoV  | N/A       | HeLa cells constitutively expressing TMPRSS2 (HeLa-TMPRSS2 cells), Vero cells, and Vero cells constitutively expressing TMPRSS2 (Vero-TMPRSS2 cells) | Western blot, qRT-PCR | TMPRSS2 |
| Kleine-Weber et al. (2018)| Germany     | MERS-CoV  | pCAGGS-based plasmids encoding VSV-G, wTMEMS-S or cleavage site mutants, expression plasmids for hTMPRSS2 and hDPP4 | 293 T, Vero E6 cells, human colorectal adenocarcinoma cell line Caco-2 | Western blot, quantitative PCR | TMPRSS2, Furin, Cathepsin L |
| Shen et al. (2017)    | China/Japan| SARS-CoV, MERS-CoV | N/A | N/A | N/A | N/A, TMPRSS2, cathepsin |
| Iwata-Yoshikawa et al. (2019) | Japan | SARS-CoV, MERS-CoV | N/A | N/A | N/A | N/A | TMPRSS2, cathepsin |

Table 1 Characteristics of included studies
Shulla 2011 slightly evidenced TMPRSS2-specific SARS-S cleavage. The resulting fragments are assumed to represent the activated S proteins operating in pseudovirus entry. It can trigger the uptake of virions into host cell endosomes (Shulla et al. 2011). Spike cleavage by TMPRSS2 takes place in the Golgi or plasma membrane, either during assembly or attachment and release (Shirato et al. 2013). Glowacka et al. demonstrated that TMPRSS2 cleaved SARS S at multiple sites inducing incomplete SARS-S shedding in cells coexpressing TMPRSS2 and SARS-S.

They also found that TMPRSS2 facilitated trans-cleavage of SARS-S, indicating that it could activate SARS S for membrane fusion (Glowacka et al. 2011). According to Matsuyama 2010, as they found that TMPRSS2 affected SARS S attached to receptors at the cell surface but not newly synthesized SARS S (Matsuyama et al. 2010). On the other hand, Reinke 2017 found that residue R667 was essential for SARS S cleavage by TMPRSS2 while the same residue was dispensable for S protein activation (Reinke et al. 2017).

Shirato 2013 found that cleavage fragments activity was required for viral spread into the host. Also, differential glycosylation of the cleavage products might reflect differential cellular localization of the corresponding cleavage processes. In contrast, TMPRSS2 might process SARS S early after import in the constitutive secretory pathway and before N-glycans are fully processed (Shirato et al. 2013).

Cleavage of ACE2

As mentioned above, studies show that SARS-CoV and SARS-CoV-2 bind to cellular receptor ACE2. Matsuyama 2010 studied the expression of ACE2 using specific antibodies, and they weakly detected ACE2 antigens in uninfected
| Study          | Domain | S protein cleavage | ACE2 cleavage | Syncytia formation | Virus replication and spread | Cathepsin L-independent entry | Immune response | TMPRSS2 expression |
|---------------|--------|--------------------|---------------|--------------------|-------------------------------|-------------------------------|----------------|------------------|
| Reinke et al. (2017) | R667; R797; 543/ R544; R563/ K566 | Residue R667 is required for SARS S processing by TMPRSS2 and trypsin. Residues N-terminal of R667 might impact proteolytic processing of SARS S | Activation of SARS S by a cellular protease is a prerequisite to membrane fusion and protease choice determines at which cellular localization membrane fusion occur | N/A | A serine protease inhibitor active against TMPRSS2 but not a cysteine protease inhibitor active against cathepsin B/L protected rodents from SARS-CoV-induced pathogenesis | Binding of SARS-CoV to ACE2 can trigger uptake of virions into host cell endosomes, where cathepsin B/L cleave and activate the S protein | N/A | Coexpression of high amounts of TMPRSS2 and SARS S results in the production of several C-terminal cleavage fragments |
| Heurich et al. (2014) | R697; R716 | Binding of SARS-S to ACE2 triggers subtle conformational rearrangements in SARS-S, which are believed to increase the sensitivity of the S protein to proteolytic digest at the border between the S1 and S2 subunits | Catalytic domain of ACE2 binds to SARS-S with high affinity. Arginine and lysine residues within ACE2 amino acids 697 to 716 are essential for ACE2 cleavage by TMPRSS2 and HAT and that ACE2 processing is required for augmentation of SARS-S-driven entry but not for SARS-S activation | N/A | Virions can be taken up into endosomes, where SARS-S is cleaved and activated | If no SARS-S-activating proteases (i.e., TMPRSS2 with ACE2) are expressed at the cell surface, virions are taken up into endosomes, where SARS-S is cleaved and activated by the pH-dependent cysteine protease cathepsin L | N/A | TMPRSS2 facilitates SARS-CoV infection via two independent mechanisms: cleavage of ACE2, which might promote viral uptake, and cleavage of SARS-S, which activates the S protein for membrane fusion |
| Glowacka et al. (2011) | N/A | TMPRSS2 cleaved SARS-S at multiple sites, generating fragments of 150, 110, 85, 55, and 45 kDa | TMPRSS2 on target cells allowed efficient SARS S-dependent cell–cell fusion | Large syncytia were frequently detected in TMPRSS2-expressing Vero E6 cells infected with SARS-CoV | N/A | Cathepsin inhibitor reduced infection by SARS-S pseudotypes, and it was not rescued by SARS-S processing by TMPRSS2 | Reduction of neutralizing activity of serum from immunized mice and less reduction of viral infectivity in TMPRSS2-expressing cells | N/A | mRNA was low or absent in brain and heart tissue. It was detected in samples from pancreas, kidney, and lung. Immunostaining for TMPRSS2 and ACE2 demonstrated strong positive staining of type II pneumocytes and alveolar macrophages |
| Study             | Domain | S protein cleavage | ACE2 cleavage | Syncytia formation | Virus replication and spread | Cathepsin L-independent entry | Immune response | TMPRSS2 expression |
|------------------|--------|--------------------|---------------|--------------------|-------------------------------|-------------------------------|----------------|-------------------|
| Shulla et al. (2011) | N/A    | There was evidence of TMPRSS2-specific SARS-S cleavage indicated by the presence of C-terminal 120- and 85-kDa S fragments | Cultures with gradually increasing levels of TMPRSS2 revealed doses ultimately eliminating full-length ACE2 | A coculture of effector and target cells indicated a tenfold increase in membrane fusion | TMPRSS2 enhanced SARS S-mediated pseudovirus entry and exhibited restricted S-specific enhancing effects | Cultures with undetectable complete ACE2 were 30-fold more susceptible to HIV-S transduction than controls | Viral RNAs were translated to generate significantly more N proteins in TMPRSS2+ cells | Inhibitors of endosomal acidification potently suppressed S mediated transductions, but it was eliminated by TMPRSS2, which fully activated SARS-S-mediated entry (1,000-fold) | N/A | N/A |
| Study          | Domain         | S protein cleavage                                                                 | ACE2 cleavage | Syncytia formation                                                                 | Virus replication and spread | Cathepsin L-independent entry | Immune response | TMPRSS2 expression |
|---------------|----------------|-----------------------------------------------------------------------------------|---------------|-----------------------------------------------------------------------------------|------------------------------|-----------------------------|----------------|-------------------|
| Matsuyama et al. (2010) | N/A            | S proteins synthesized in either Vero or Vero-TMPRSS2 cells were not cleaved       | N/A           | Large syncytia were observed in Vero-TMPRSS2 cells but not in Vero cells          | N/A                          | Treatment with a cathepsin inhibitor caused a decrease of SARS-CoV entry into Vero cells but not into Vero-TMPRSS2 cells | N/A            | TMPRSS2 antigens were detected in type I pneumocytes Weak staining of ACE2 antigens was detected in enlarged type II pneumocytes Mild lesions: type I pneumocytes resembled TMPRSS2-expressing cells, more than ACE2-expressing cells, SARS-CoV antigens were detected in the cytoplasm Severe lesions: marked immunostaining of TMPRSS2 and ACE2 antigens was detected in the cytoplasm of enlarged type II pneumocytes. The presence of SARS-CoV antigens did not correlate with the presence of either ACE2 or TMPRSS2 antigens |
Table 2 (continued)

| Study                        | Domain | S protein cleavage                        | ACE2 cleavage | Syncytia formation | Virus replication and spread | Cathepsin L-independent entry | Immune response | TMPRSS2 expression |
|------------------------------|--------|------------------------------------------|---------------|-------------------|------------------------------|-------------------------------|-----------------|-------------------|
| Shirato et al. (2013)        | N/A    | Lysine residues at the cleavage site in the viral S protein are a target for trypsin | N/A           | The syncytia were more pronounced in Vero-TMPRSS2 cells than in the exogenous protease treated parental Vero cells | Protein on the MERS-CoV particle is sufficient for the induction of cell-cell fusion in the absence of protein synthesis | The virus titer in the Vero-TMPRSS2 cell medium was 1 or 2 log units higher than that in the parental Vero cell | Cell-cell fusion mediated cytotoxicity may potentially cause the immune system to develop severe inflammation in response to viral infection | N/A               |
| Kleine- Weber et al. (2018)  | S2’ site (amino acids RSAR) for activating proteases; S1/ S2 site (amino acids RSVR) for furin; AFNH motif for endosomal cysteine protease (Cathepsin L) | Alteration of the S1/S2 site markedly reduced entry into Caco-2 but not 293 T, 293 T + DPP4 or Vero E6 cells An intact S2’ site was universally required for S protein driven entry None of the mutations introduced into the S1/S2 site markedly reduced entry into Vero E6 cells The second but not the first arginine within the S2’ site was sufficient for efficient S protein-driven entry into Caco-2 cells | N/A           | N/A | Transduction mediated by wildtype MERS-S was comparable for Vero E6 and Caco-2 cells, and generally higher as compared to untransfected 293 T cells 293 T cells previously transfected with expression plasmid for DPP4, transduction levels were as high as for Vero E6 and Caco-2 cells Preincubation of Caco-2 cells with protease inhibitors showed that entry driven by S proteins lacking an intact S1/S2 site was dependent on TMPRSS2 but not cathepsin L activity | Mutation of the cathepsin L site had no impact on S protein-driven entry Entry driven by MERS-S WT and S protein variants with mutations in the S1/S2 site was inhibited by Cathepsin L inhibitor treatment Entry mediated by the S protein mutants with inactivated S1/S2 site was rescued by TMPRSS2 with reduced efficiency as compared to MERS-S WT | Applicable levels of TMPRSS2 mRNA were only detected in Caco-2 cells and lung tissue | N/A               |
Table 2 (continued)

| Study            | Domain | S protein cleavage | ACE2 cleavage | Syncytia formation | Virus replication and spread | Cathepsin L-independent entry | Immune response | TMPRSS2 expression |
|------------------|--------|--------------------|---------------|--------------------|-------------------------------|-------------------------------|-----------------|--------------------|
| Shen et al. (2017) | N/A    | Cleavage site is located at the S1/S2 boundary and another is within S2 upstream of the putative fusion peptide (S2'). After cleavage of spike, S1 and S2 domains remain associated by noncovalently, but not disulfide bonds | N/A | SARS-CoV entry increased 2.6-fold in the presence of TMPRSS2 siRNA targeting TMPRSS2 caused a five-fold decrease in SARS-CoV entry into Calu-3 cells. The levels of SARS-CoV RNA are nine-fold higher in cells expressing active TMPRSS2 than in cells expressing enzymatically inactive TMPRSS2 | N/A | N/A | N/A                |
| Study                  | Domain | S protein cleavage | ACE2 cleavage | Syncytia formation | Virus replication and spread | Cathepsin L-independent entry | Immune response                                                                 | TMPRSS2 expression |
|-----------------------|--------|--------------------|---------------|--------------------|-----------------------------|--------------------------------|--------------------------------------------------------------------------------|------------------|
| Iwata-Yoshikawa et al. (2019) (SARS-CoV) | N/A    | N/A                | N/A           | N/A                | Strongly antigen-positive cells were observed in the bronchiolar epithelium of WT mice infected with SARS-CoV Some antigen positive cells were seen in alveoli from both WT and TMPRSS2-KO mice | N/A              | WT mice showed clear loss of body weight, it was not observed in TMPRSS2-KO mice (day 2: $p < 0.05$; days 3 and 4: $p < 0.0001$) Concentrations of FGF-basic (day 3: $p < 0.0001$), keratinocyte-derived chemokine/CXCL1 (day 2: $p < 0.01$), IL-12 (p40/p70) (day 2: $p < 0.01$), IL-4 (day 3: $p < 0.05$), and IL-10 (day 3: $p < 0.05$) were significantly lower than those in WT mice A transient increase in TLR3 expression in the lungs of TMPRSS2-KO mice was observed at 6 h, but not in WT mice ($p < 0.05$) IFN-alpha (day 3: $p < 0.01$) and IFN-beta (day 3: $p < 0.01$) mRNA expression levels were higher in WT mice than in TMPRSS2-KO mice | N/A              |
| Study | Domain | S protein cleavage | ACE2 cleavage | Syncytia formation | Virus replication and spread | Cathepsin L-independent entry | Immune response | TMPRSS2 expression |
|-------|--------|--------------------|---------------|-------------------|-----------------------------|-----------------------------|----------------|------------------|
| Iwata-Yoshikawa et al. (2019) (MERS-CoV) | N/A    | N/A               | N/A            | N/A               | On day 1, many viral antigen-positive cells were observed in the bronchi and alveolar areas of hDPP4-Tg mice; there were none in the bronchi and only a few in the alveoli of TMPRSS2-KO Tg mice. On day 3, many viral antigen-positive cells were present in these areas in hDPP4-Tg mice, but there were fewer in TMPRSS2-KO Tg mice. | hDPP4-Tg mice showed a temporary and mild loss of body weight; however, only very slight changes were observed in TMPRSS2-KO Tg mice (days 6 and 7; \( p < 0.001 \)) | Titers of neutralizing antibodies in sera from TMPRSS2-KO Tg mice were significantly lower than those in sera from hDPP4-Tg mice (\( p < 0.05 \)) | Concentrations of FGF-basic (day 7: \( p < 0.01 \)), GM-CSF (day 5: \( p < 0.05 \)), MIG/CXCL9 (day 5: \( p < 0.05 \)), IL-17 (day 5: \( p < 0.05 \)), and TNF-alpha (day 5: \( p < 0.05 \)) in the lungs of TMPRSS2-KO Tg mice were lower than those in the lungs of hDPP4-Tg mice. Expression levels of IL-6 (day 7: \( p < 0.05 \)) were higher in TMPRSS2-KO Tg mice than in hDPP4-Tg mice. IFN-alpha4 (day 2: \( p < 0.05 \)) and IFN-beta (day 2: \( p < 0.001 \), day 3: \( p < 0.01 \)) mRNA expression levels were higher in hDPP4-Tg mice than in TMPRSS2-KO Tg mice. | N/A |
Table 2 (continued)

| Study          | Domain                     | S protein cleavage | ACE2 cleavage | Syncytia formation | Virus replication and spread | Cathepsin L-independent entry | Immune response | TMPRSS2 expression |
|----------------|----------------------------|--------------------|---------------|--------------------|-------------------------------|-----------------------------|-----------------|-------------------|
| Hoffmann et al. (2020) | SARS S: amino acids for S1/S2, and 793 to 800 | Efficient proteolytic processing of SARS-2-S in human cells evidenced the presence of several arginine residues at the S1/S2 cleavage site of SARS-2-S but not SARS-S | Most amino acid residues essential for ACE2 binding by SARS-S were conserved in SARS-CoV-2 infected BHK-21 cells expressing ACE2 but not parental cells with high efficiency after 16 h (p<0.01) | Most human cell lines and the animal cell lines Vero and MDCKII were susceptible to entry driven by SARS-S and SARS-2-S facilitated entry into an identical spectrum of cell lines | When using a cathepsin B/L blocker, inhibition of entry into TMPRSS2 + Caco-2 cells was less efficient compared to 293 T cells | Camostat mesylate did not interfere with SARS-2-S-driven entry into the TMPRSS2- cell lines 293 T and Vero (p<0.001) | Four sera obtained from three convalescent SARS patients inhibited SARS-S-driven entry in a concentration-dependent manner, and these sera also reduced SARS-2-S-driven entry, although with lower efficiency compared to SARS-S | N/A |
|                | SARS-2-S: amino acids 676 to 688 for S1/S2, and 811 to 818 for S2’ | The S2’ cleavage site of SARS-2-S was similar to that of SARS-S | Directed expression of human and bat ACE2 allowed SARS-2-S- and SARS-S-driven entry into otherwise non-susceptible BHK-21 cells (p<0.001) | Antiserum against human ACE2 blocked SARS-S- and SARS-2-S-driven entry (<0.001) | Neutralization of authentic SARS-CoV-2 (p<0.001), and inhibited SARS- and SARS-2-S-driven entry into Calu-3 cells (p<0.001), and also reduced Calu-3 infection with VSV-G-driven entry into Calu-3 cells (p<0.001) | Directed expression of TMPRSS2 rescued SARS-2-S-driven entry from inhibition by cathepsin B/L blocker (p<0.001) | Ammonium chloride (endosome acidification blocker) strongly inhibited SARS-2-S- and SARS-S-driven entry into TMPRSS2- 293 T cells (p<0.001) | Camostat partially blocked SARS-2-S-driven entry into Caco-2 and Vero-TMPRSS2 cells (p<0.001) | Full inhibition was attained with camostat and an inhibitor of Cathepsin B/L (p<0.001) |
| Study                  | Domain | S protein cleavage | ACE2 cleavage | Syncytia formation               | Virus replication and spread | Cathepsin L-independent entry | Immune response | TMPRSS2 expression |
|-----------------------|--------|--------------------|---------------|----------------------------------|------------------------------|-------------------------------|-----------------|--------------------|
| Matsuyama et al. (2020) | N/A    | N/A                | N/A           | In five cases among seven, clear cytopathic effect with detachment/floating and syncytium formation developed at 2 or 3 days | The amount of SARS-CoV-2 RNAs in the culture supernatants of Vero, Calu-3, and A549 cells after 48 h was low and was measurably higher when VeroE6 cells were used. | N/A | N/A | The messenger RNA expression level of TMPRSS2 in VeroE6/TMPRSS2 cells is ~tenfold higher than in normal human lung tissue and other human cell lines |
| Bilinska et al. (2020)  | N/A    | N/A                | N/A           | Expression profiling data for murine OE indicate that ACE2 is mainly expressed in non-neuronal cells. | SARS-CoV-2 virus accumulates in sustentacular cells first and, by interfering with their metabolism, affects the function of olfactory receptor neurons. | N/A | N/A | TMPRSS2 is widely expressed in both neuronal and non-neuronal cells, higher levels in non-neuronal cells |
type II pneumocytes. However, the authors detected immunostaining of TMPRSS2 and ACE2 antigens in severe lesions (Matsuyama et al. 2010). Glowacka et al. also detected intense positive staining of both proteins in type II pneumocytes and alveolar macrophages (Glowacka et al. 2011). In Shulla et al. (2011), TMPRSS2 eliminated full-length ACE2 in a dose-dependent manner, but ACE2 colocalized to TMPRSS2-containing regions when TMPRSS2 scarce and showed that it required an enzymatic activity of TMPRSS2 for this association.

Interestingly, when these two proteins were expressed in separate cells, SARS-CoV entry into host cells was not higher than those expressing one of them. It indicates that the priming of ACE2 by TMPRSS2 was necessary for virus entry (Shulla et al. 2011). Heurich 2013 concluded that TMPRSS2 facilitates SARS-CoV infection through cleavage of ACE2, which might promote viral uptake (Heurich et al. 2014).

The catalytic domain of ACE2 binds to SARS-S with high affinity, and it triggers conformational rearrangements that could increase proteolysis sensitivity. In that sense, arginine and lysine residues within ACE2 amino acids 697–716 are essential for ACE2 cleavage by TMPRSS2.

Augmentation of SARS-S-driven entry requires the processing of ACE2 but not for its activation (Heurich et al. 2014). It is noteworthy that, according to Hoffmann 2020, most amino acid residues essential for ACE2 binding by SARS-S were conserved in SARS-2-S. In this study, authentic SARS-CoV-2 infected cells expressing ACE2 with high efficiency but not cells without this receptor (p < 0.01) and antiserum against human ACE2 blocked SARS-S- and SARS-2-S-driven entry (p < 0.001) (Hoffmann et al. 2020).

### Syncytia formation

Some studies show that syncytia formation is more frequent and pronounced between SARS-CoV infected cells (or even SARS-S expressing cells) expressing TMPRSS2 and between MERS-CoV infected cells expressing TMPRSS2 (Matsuyama et al. 2010; Glowacka et al. 2011; Shulla et al. 2011; Shirato et al. 2013). Interestingly, outcomes from Matsuyama et al. (2010) indicate that TMPRSS2 expression must oppose that of SARS S to induce membrane fusion. Syncytia formation was not induced in cells that did not express TMPRSS2, nor between TMPRSS2 and SARS-S and cells without TMPRSS2. However, large syncytia formed when TMPRSS2 was expressed either in target cells or both in the target and producer cells (Matsuyama et al. 2010). In that sense, SARS S can be activated for virus-cell and cell–cell fusion when TMPRSS2 is expressed on viral target cells (Glowacka et al. 2011; Shulla et al. 2011). Syncytia formation is frequent in cells expressing TMPRSS2 infected with SARS-CoV-2 (Matsuyama et al. 2020).
Virus replication and spread

In general, cells expressing TMPRSS2 were more susceptible to virus entry and spread into host cells. Also, when compared to other serine proteases, TMPRSS2 was more effective in enhancing SARS-S-mediated entry (Glowacka et al. 2011; Shulla et al. 2011; Heurich et al. 2014; Reinke et al. 2017). TMPRSS2 expression was also associated with increased amounts of viral RNA. Shulla et al. found that SARS N RNA was ninefold more in TMPRSS2-expressing cells, and this RNA translated to generate significantly more N proteins (p < 0.0005) (Shulla et al. 2011). Viruses spread by the increased expression of virus antigens in cells expressing TMRPSS2. Iwata-Yoshikawa et al. observed only very weak SARS-S antigen positivity in TMPRSS2-Knock Out (KO) mice than wild-type mice at day one postinfection. Lungs of TMRPSS2-KO mice showed lower viral replication with no significant differences in the titers of neutralizing antibodies in serum samples from either group (Iwata-Yoshikawa et al. 2019). According to Shen et al., SARS-CoV entry increased in the presence of TMPRSS2, and levels of SARS-CoV RNA were higher in cells expressing active TMPRSS2 than in cells expressing enzymatically inactive TMRPSS2 (Shen et al. 2017).

We found similar results with MERS-S. Shirato et al. evidenced higher virus titer in the Vero-TMPRSS2 cell medium than in the parental Vero cell medium (Shirato et al. 2013). MERS-CoV replicated more slowly, and antigen positivity in TMRPSS2-KO mice was fewer or absent at the first and third postinfection days (Iwata-Yoshikawa et al. 2019).

For the recent SARS-CoV-2, Matsuyama et al. evidenced that viral RNA copies in specimens with cytopathic effects developed within two days were more significant than those in the other specimens. They used Vero E6/TMPRSS2 cells and found more than 100 times higher viral RNA copies than Vero E6, which also showed higher amounts compared to other cell types used (Matsuyama et al. 2020). In gut epithelial cells, Zang et al. demonstrated that TMPRSS2 alone did not mediate viral infection. However, co-expression of TMRPSS2 with ACE2 resulted in enhanced infectivity, inducing S protein cleavage and exposing the fusion peptide for efficient viral entry (Zang et al. 2020).

Further analyses using protease inhibitors support these results. In the study performed by Kleine-Weber et al. (2018), preincubation of Caco-2 cells with protease inhibitors showed that entry driven by MERS S lacking an intact S1/S2 site was dependent on TMPRSS2, indicating a dominant role of TMRPSS2 in MERS-S-driven entry. Reinke et al., also used a serine protease inhibitor and found that it protected rodents from SARS-CoV-induced pathogenesis, while a cysteine protease inhibitor active against cathepsin B/L did not (Reinke et al. 2017). Finally, Hoffmann et al. used camostat mesylate treatment (a drug active against TMRPSS2) and found a significant reduction in SARS-S- and SARS-2-S-mediated entry into Calu-3 and human lung cells. It also reduced the infection by authentic SARS-CoV-2 into Calu-3 cells. On the other hand, treatment of other cell lines (Caco-2 and Vero-TMPRSS2) partially blocked SARS-2-S-driven entry, but when they added an inhibitor of Cathepsin B/L, complete inhibition was attained (Hoffmann et al. 2020).

Bilinska et al. used a mouse model and determined whether cells in the olfactory epithelium (OE) express the obligatory receptors for entry of the SARS-CoV-2 virus by using RNAseq, RT-PCR, in situ hybridization, Western blot, and immunocytochemistry. Their mouse model showed that, with older age, amounts of ACE2 protein increased in the OE, as did gene expression of TMRPSS2. Sustentacular cells were identified as the cell type that expressed both SARS-CoV-2 host receptors required for cell entry. Results suggest that the SARS-CoV-2 virus accumulates in sustentacular cells first and, by interfering with their metabolism, affects the function of olfactory receptor neurons (Bilinska et al., 2020).

Cathepsin L-independent entry and spread

As mentioned above, some studies have used Cathepsin B/L inhibitors to study Spike protein-mediated entry under these conditions or even evaluate cleavage by this cysteine protease. Spike protein cleavage and activation by pH-dependent cathepsin B/L occurs in the endosome (Reinke et al. 2017). Studies have shown that inhibition of Cathepsin L decreased virus entry into cells with no expression of TMRPSS2 on the cell surface. Expression of TMRPSS2 could even activate Spike protein and enhance SARS-S-mediated entry (Matsuyama et al. 2010; Glowacka et al. 2011; Shulla et al. 2011). Kleine-Weber et al. found similar results for MERS S in which they introduced mutations into different cleavage sites. They found that mutation of a single arginine within S1/S2 reduced entry into Caco-2 cells by 4.5 to 29.4-fold (p < 0.001). Mutation of any single arginine at the S2′ site had only a minor, statistically significant, effect on S protein-mediated transduction of Vero E6 cells (p < 0.001), and mutation of S2′ abrogated MERS-S activation by TMRPSS2. However, entry mediated by the S protein mutants with inactivated S1/S2 site was rescued by TMRPSS2 in cells previously treated with Cathepsin L inhibitor (Kleine-weber et al. 2018). For SARS-CoV-2, Hoffmann et al. also evidenced that expression of TMRPSS2 rescued SARS-2-S-driven entry from inhibition of cathepsin B/L. It is noteworthy that this study also reported a residual Spike protein priming by cathepsin B/L in a cell line when camostat mesylate was used. However, S protein priming by TMRPSS2 but not cathepsin B/L is still essential for viral entry into primary target cells and viral spread in the infected host (Hoffmann et al. 2020).
Discussion

Members of the betacoronavirus genus such as SARS-CoV and MERS-CoV have caused significant outbreaks of respiratory disease. It motivates the rapid understanding of virus interactions with human cells and immunopathology. With the novel coronavirus (SARS-CoV-2) outbreak, findings allowed to establish an essential similarity between this and previous Beta-CoVs. In that sense, SARS-S and SARS-2-S share approximately 76% amino acid identity, which makes it essential to know the similarities and differences between the mechanisms of virus entry and spread into host cells (Hoffmann et al. 2020).

SARS-CoV and SARS-CoV-2 bind to the cell surface receptor ACE2, while MERS-CoV binds to DPP4 (Hoffmann et al. 2020; Zhou et al. 2020). Studies described two critical mechanisms for host cell entry, depending on the availability of cellular proteases. When TMPRSS2 coexpresses with the target cell’s surface receptors, Spike protein can be activated and then induce virus-cell membrane fusion. When cell surface proteases are not expressed, Spike protein binds to the cell surface’s receptor, resulting in virions uptake into endosomes. In this case, Spike is cleaved and activated by pH-dependent cysteine protease Cathepsin B/L, initiating virus-endosome membrane fusion and later release of the viral genetic material into the cytosol (Heurich et al. 2014; Shen et al. 2017).

Immunostaining for TMPRSS2 and ACE2 demonstrated intense positive staining of type II pneumocytes and alveolar macrophages. Similar results were found in severe lesions of lung tissue, and mRNA levels of TMPRSS2 have been detected in lung tissue (Matsuyama et al. 2010; Glowacka et al. 2011; Kleine-weber et al. 2018). These results show that TMPRSS2 facilitates SARS-CoV infection by cleavage of ACE2, which might promote viral uptake, and cleavage of SARS-S, which activates the S protein for membrane fusion (Heurich et al. 2014).

On the other hand, the expression of receptors and proteases requires a specific spatial orientation to allow S protein activation, S protein-mediated entry and spread into cells. If TMPRSS2 is coexpressed with SARS-S in the same cell, cleavage results in SARS-S shedding into the supernatants, where the S protein fragments could function as antibody decoys. If TMPRSS2 expresses on viral target cells, it can activate SARS-S for virus-cell and cell–cell fusion. Also, relevant targets correspond to cells in which both the ACE2 and TMPRSS2 entry factors are present in the same cells simultaneously (Glowacka et al. 2011; Shulla et al. 2011). The results of the study performed by Bilinska et al., in which older mice expressed increasing levels of ACE2 and TMPRSS2, may explain why animals (and humans) are more susceptible to COVID-19 infection when they reach old age (Bilinska et al. 2020).

Evidence shows that TMPRSS2 is essential for virus spread into host cells as more significant amounts of viral RNA and/or S protein have been detected in cells expressing this serine protease compared to TMPRSS2-negative cells and large syncytia forms when TMPRSS2 is present. This process indicates a significant cytopathic effect. Cell–cell mediated cytotoxicity and viral replication may cause the immune system to develop severe inflammation in response to viral infection (Shirato et al. 2013). However, outcomes assessing immune response and the role of TMPRSS2 in immunopathology are unclear.

Iwata-Yoshikawa et al. evaluated the immune response in lung cells and the expression of TMPPRSS2. TMPPRSS2 shows the proliferation of Th2 profile and contributed to inflammatory reactions after Toll-Like Receptor 3 (TLR3) stimulation without the control of endogenous promoter transcription mRNA of chemokines. It also induced the expression of interleukins and interferons (Iwata-Yoshikawa et al. 2019). Its expression results in a focal inflammatory infiltration around the bronchi and the alveoli. In contrast, the expression TLR3 showed lower viral replication. The fragments produced by the TMPPRSS2 do not demonstrate a relationship with long-term isotypes in the adaptative immune response. Also, chemokine, IFN-alpha4, IFN-beta, IL-12, IL-4, and IL-10 and viral mRNA, showed increasing levels daily postinfection with a significant association with the inflammatory pathogenesis (Glowacka et al. 2011; Iwata-Yoshikawa et al. 2019).

Finally, using drugs to inhibit TMPPRSS2 or other proteases such as Cathepsin B/L has allowed determining alternative mechanisms for S protein activation. In that sense, studies demonstrate that virus spread depends on TMPPRSS2 activity, but there could be a residual effect of Cathepsin B/L in S protein priming when TMPPRSS2 inhibits. This reaction could be explained by using alternative sites for S protein activation by Cathepsin L but not by TMPPRSS2 (Matsuyama et al. 2010; Glowacka et al. 2011; Shulla et al. 2011; Reinke et al. 2017; Kleine-weber et al. 2018; Iwata-Yoshikawa et al. 2019; Hoffmann et al. 2020). Candidate drugs for post-exposure prophylaxis of SARS-CoV-2 infection could be clinically proven drugs such as camostat mesilate, preventing virus-host cell entry by inhibiting TMPPRSS2. In addition, nafamostat mesilate may also inhibit cell entry of SARS-CoV-2 due to the amino acid sequence homology between Spike proteins of MERS-Cov and SARS-CoV-2. Cell culture experiments with simian Vero E6 cells infected with SARS-CoV-2, was shown to be inhibitive against SARS-CoV-2 infection, suggesting that
nafamostat mesilate could prevent SARS-CoV-2 infection (Wang et al. 2020a, b; Mckee et al. 2020).

Conclusions

Emerging coronaviruses can constitute a severe threat to human health. Accumulating evidence suggests that TMPRSS2 is an essential protease for virus replication. However, there is a need for further research and many knowledge gaps exist. The expression of TMPRSS2 and the human proteases on Spike protein plays a critical role in initiating and propagating the virus, the transmissibility, and viral tropism and pathogenesis in the lung.

This review highlighted its critical molecular role in membrane fusion and the impact on viral mRNA replication, then promoting/driving pathogenesis and resistance. Many proteases have been discovered, and maybe an intrinsic mechanism leading to the rapid progress of ARDS in patients.

Identifying molecular mechanisms, advancements in virus genomics, and understanding their consequences will be crucial for developing novel therapeutic strategies to overcome the infection in a precision medicine era.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00203-021-02727-3.

Funding The authors had no funding.

Declarations

Conflict of interest The authors have no conflict of interest.

Ethical approval This is a scoping review; no ethical approval was needed.

Informed consent No informed consent was needed.

References

Bilinska K et al (2020) Expression of the SARS-CoV-2 entry proteins, ACE2 and TMPRSS2, in cells of the olfactory epithelium: identification of cell types and trends with age. ACS Chem Neurosci 11(11):1555–1562. https://doi.org/10.1021/acschemneuro.0c00210

Glowacka I et al (2011) Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol 85(9):4122–4134. https://doi.org/10.1128/JVI.02232-10

Heurich A et al (2014) TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J Virol 88(2):1293–1307. https://doi.org/10.1128/JVI.02202-13

Hoffmann M et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181:1–10. https://doi.org/10.1016/j.cell.2020.02.052

Huang C et al (2020) ‘Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.’ Lancet 395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5

Iwata-Yoshikawa N et al (2019) TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection. J Virol 93(6):1–15

Kleine-weber H et al (2018) Functional analysis of potential cleavage sites in the MERS-coronavirus spike protein. Sci Rep 8(16597):1–11. https://doi.org/10.1038/s41598-018-34859-w

Matsuyama S et al (2010) Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol 84(24):12658–12664. https://doi.org/10.1128/JVI.01542-10

Matsuyama S et al (2020) Enhanced isolation of SARS-CoV-2 by TMPRSS2- expressing cells. Proc Natl Acad Sci 117(13):7001–7003. https://doi.org/10.1073/pnas.2002589117

Mckee D et al (2020) Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacol Res 157(2020):1–9

Peters M et al (2017) Scoping reviews. In: Aromataris E, Munn Z (eds) Joanna Briggs Institute reviewer’s manual. The Joanna Briggs Institute, Australia

Reinke LM et al (2017) Different residues in the SARS-CoV spike protein determine cleavage and activation by the host cell protease TMPRSS2. PLoS One 12(6):1–15. https://doi.org/10.1371/journal.pone.0179177

Shen LW et al (2017) TMPRSS2: a potential target for treatment of influenza virus and coronaviruses infections. Biochimie 142:1–10. https://doi.org/10.1016/j.bioch.2017.07.016

Shirato K, Kawase M, Matsuyama S (2013) Middle east respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J Virol 87(23):12552–12561. https://doi.org/10.1128/JVI.01890-13

Shulla A et al (2011) A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J Virol 85(2):873–882. https://doi.org/10.1128/JVI.02062-10

Wang C et al (2020a) A novel coronavirus outbreak of global health concern. Lancet 395:470–473. https://doi.org/10.1016/S0140-6736(20)30185-9

Wang M et al (2020b) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30(3):269–271

WHO (2020) WHO Director-General’s opening remarks at the media briefing on COVID-19—11 March 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed 10 Jan 2021

Zang R et al (2020) TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci. Immunol. 5(47):1–14. https://doi.org/10.1126/sciimmunol.abc3582

Zhou P et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:270–273. https://doi.org/10.1038/s41586-020-2012-7

Zhu N et al (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382(8):727–733. https://doi.org/10.1056/NEJMoa2001017

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.